Antibody-Mediated Rejection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major antibody-mediated rejection markets reached a value of US$ 112.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 401.8 Million by 2034, exhibiting a growth rate (CAGR) of 12.29% during 2024-2034.
The antibody-mediated rejection market has been comprehensively analyzed in IMARC's new report titled "Antibody-Mediated Rejection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Antibody-mediated rejection is a significant complication in organ transplantation, where the immune system of the recipient mounts an attack against the transplanted organ due to the presence of donor-specific antibodies. These antibodies recognize and target antigens on the donor organ's cells, leading to inflammation and damage. The symptoms of this ailment can vary depending on the affected organ, but common signs include fever, reduced organ function, and swelling or tenderness at the transplant site. In the case of kidney transplants, changes in urine output and elevated creatinine levels may also be observed. The diagnosis of this illness is usually based on the patient's clinical features and medical history. A healthcare provider will also conduct a biopsy of the transplanted organ to detect certain histological changes, serological testing to identify donor-specific antibodies and advanced imaging for cardiac transplants. Flow cytometry and various other molecular diagnostic methods are further utilized to confirm an early diagnosis.
The increasing incidences of solid organ transplants that can stimulate the graft's generation of antibodies specific for foreign antigens, particularly major histocompatibility antigens, are primarily driving the antibody-mediated rejection market. In addition to this, the escalating utilization of effective medications, including immunosuppressants like calcineurin inhibitors and corticosteroids, to manage the disease and prevent graft rejection in patients is also creating a positive outlook for the market. These therapeutic agents work by suppressing the immune response and mitigating the antibody-mediated damage to the transplanted organ. Moreover, the widespread adoption of innovative diagnostic tools and assays for early detection of the ailment, which enable timely identification of the rejection process as well as allow for prompt intervention, is further bolstering the market growth. Apart from this, the inflating application of plasmapheresis procedures on account of their numerous advantages, such as reducing inflammation, improving the function of the transplanted organ, enhancing the treatment outcomes for patients, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intravenous immunoglobulin therapy, since it helps to remove harmful antibodies from the recipient's bloodstream and modulate the immune response, thereby increasing graft survival rates, is expected to drive the antibody-mediated rejection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the antibody-mediated rejection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for antibody-mediated rejection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the antibody-mediated rejection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the antibody-mediated rejection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the antibody-mediated rejection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current antibody-mediated rejection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the antibody-mediated rejection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the antibody-mediated rejection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the antibody-mediated rejection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of antibody-mediated rejection across the seven major markets?
What is the number of prevalent cases (2018-2034) of antibody-mediated rejection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of antibody-mediated rejection by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with antibody-mediated rejection across the seven major markets?
What is the size of the antibody-mediated rejection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of antibody-mediated rejection?
What will be the growth rate of patients across the seven major markets?
Antibody-Mediated Rejection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for antibody-mediated rejection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the antibody-mediated rejection market?
What are the key regulatory events related to the antibody-mediated rejection market?
What is the structure of clinical trial landscape by status related to the antibody-mediated rejection market?
What is the structure of clinical trial landscape by phase related to the antibody-mediated rejection market?
What is the structure of clinical trial landscape by route of administration related to the antibody-mediated rejection market?
The antibody-mediated rejection market has been comprehensively analyzed in IMARC's new report titled "Antibody-Mediated Rejection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Antibody-mediated rejection is a significant complication in organ transplantation, where the immune system of the recipient mounts an attack against the transplanted organ due to the presence of donor-specific antibodies. These antibodies recognize and target antigens on the donor organ's cells, leading to inflammation and damage. The symptoms of this ailment can vary depending on the affected organ, but common signs include fever, reduced organ function, and swelling or tenderness at the transplant site. In the case of kidney transplants, changes in urine output and elevated creatinine levels may also be observed. The diagnosis of this illness is usually based on the patient's clinical features and medical history. A healthcare provider will also conduct a biopsy of the transplanted organ to detect certain histological changes, serological testing to identify donor-specific antibodies and advanced imaging for cardiac transplants. Flow cytometry and various other molecular diagnostic methods are further utilized to confirm an early diagnosis.
The increasing incidences of solid organ transplants that can stimulate the graft's generation of antibodies specific for foreign antigens, particularly major histocompatibility antigens, are primarily driving the antibody-mediated rejection market. In addition to this, the escalating utilization of effective medications, including immunosuppressants like calcineurin inhibitors and corticosteroids, to manage the disease and prevent graft rejection in patients is also creating a positive outlook for the market. These therapeutic agents work by suppressing the immune response and mitigating the antibody-mediated damage to the transplanted organ. Moreover, the widespread adoption of innovative diagnostic tools and assays for early detection of the ailment, which enable timely identification of the rejection process as well as allow for prompt intervention, is further bolstering the market growth. Apart from this, the inflating application of plasmapheresis procedures on account of their numerous advantages, such as reducing inflammation, improving the function of the transplanted organ, enhancing the treatment outcomes for patients, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intravenous immunoglobulin therapy, since it helps to remove harmful antibodies from the recipient's bloodstream and modulate the immune response, thereby increasing graft survival rates, is expected to drive the antibody-mediated rejection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the antibody-mediated rejection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for antibody-mediated rejection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the antibody-mediated rejection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the antibody-mediated rejection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the antibody-mediated rejection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current antibody-mediated rejection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the antibody-mediated rejection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the antibody-mediated rejection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the antibody-mediated rejection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of antibody-mediated rejection across the seven major markets?
What is the number of prevalent cases (2018-2034) of antibody-mediated rejection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of antibody-mediated rejection by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with antibody-mediated rejection across the seven major markets?
What is the size of the antibody-mediated rejection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of antibody-mediated rejection?
What will be the growth rate of patients across the seven major markets?
Antibody-Mediated Rejection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for antibody-mediated rejection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the antibody-mediated rejection market?
What are the key regulatory events related to the antibody-mediated rejection market?
What is the structure of clinical trial landscape by status related to the antibody-mediated rejection market?
What is the structure of clinical trial landscape by phase related to the antibody-mediated rejection market?
What is the structure of clinical trial landscape by route of administration related to the antibody-mediated rejection market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANTIBODY-MEDIATED REJECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANTIBODY-MEDIATED REJECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANTIBODY-MEDIATED REJECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ANTIBODY-MEDIATED REJECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANTIBODY-MEDIATED REJECTION - UNMET NEEDS
10 ANTIBODY-MEDIATED REJECTION - KEY ENDPOINTS OF TREATMENT
11 ANTIBODY-MEDIATED REJECTION - MARKETED PRODUCTS
11.1 List of Antibody-Mediated Rejection Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ANTIBODY-MEDIATED REJECTION - PIPELINE DRUGS
12.1 List of Antibody-Mediated Rejection Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ANTIBODY-MEDIATED REJECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ANTIBODY-MEDIATED REJECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANTIBODY-MEDIATED REJECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Antibody-Mediated Rejection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Antibody-Mediated Rejection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Antibody-Mediated Rejection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Antibody-Mediated Rejection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Antibody-Mediated Rejection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Antibody-Mediated Rejection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Antibody-Mediated Rejection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Antibody-Mediated Rejection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Antibody-Mediated Rejection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Antibody-Mediated Rejection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Antibody-Mediated Rejection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Antibody-Mediated Rejection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Antibody-Mediated Rejection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Antibody-Mediated Rejection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Antibody-Mediated Rejection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Antibody-Mediated Rejection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
16 ANTIBODY-MEDIATED REJECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANTIBODY-MEDIATED REJECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANTIBODY-MEDIATED REJECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANTIBODY-MEDIATED REJECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANTIBODY-MEDIATED REJECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANTIBODY-MEDIATED REJECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ANTIBODY-MEDIATED REJECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANTIBODY-MEDIATED REJECTION - UNMET NEEDS
10 ANTIBODY-MEDIATED REJECTION - KEY ENDPOINTS OF TREATMENT
11 ANTIBODY-MEDIATED REJECTION - MARKETED PRODUCTS
11.1 List of Antibody-Mediated Rejection Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ANTIBODY-MEDIATED REJECTION - PIPELINE DRUGS
12.1 List of Antibody-Mediated Rejection Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ANTIBODY-MEDIATED REJECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ANTIBODY-MEDIATED REJECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANTIBODY-MEDIATED REJECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Antibody-Mediated Rejection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Antibody-Mediated Rejection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Antibody-Mediated Rejection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Antibody-Mediated Rejection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Antibody-Mediated Rejection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Antibody-Mediated Rejection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Antibody-Mediated Rejection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Antibody-Mediated Rejection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Antibody-Mediated Rejection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Antibody-Mediated Rejection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Antibody-Mediated Rejection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Antibody-Mediated Rejection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Antibody-Mediated Rejection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Antibody-Mediated Rejection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Antibody-Mediated Rejection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Antibody-Mediated Rejection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Antibody-Mediated Rejection - Access and Reimbursement Overview
16 ANTIBODY-MEDIATED REJECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANTIBODY-MEDIATED REJECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANTIBODY-MEDIATED REJECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
